Fibrinogen, COPD and Mortality in a Nationally Representative U.S. Cohort

References

• Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370:765–773.
   PubMed Web of Science ®Google Scholar
• Minino AM, Xu J, Kochanek KD. Death in the United States, 2008. National Vital Statistics Reports 2010; 59:1–72.
   Google Scholar
• Burrows B, Strauss RH, Niden AH. Chronic Obstructive Lung Disease .3. Interrelationships of Pulmonary Function Data. Amer Rev Respir Dis 1965; 91:861–868.
   PubMed Web of Science ®Google Scholar
• Fletcher C, Peto R, Tinker CM, Speizer FE. The natural history of chronic bronchitis and emphysema. Oxford University Press, Oxford, UK, 1976.
   Google Scholar
• Peto R, Speizer FE, Cochrane AL The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis 1983; 128:491–500.
   PubMed Web of Science ®Google Scholar
• Anthonisen NR. The British hypothesis revisited. Euro Respir J 2004; 23:657–658.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Prescott E. Update on the “Dutch hypothesis” for chronic respiratory disease. Thorax 1998; 53 Suppl 2:S15–S19.
   Google Scholar
• Sin DD, Man SF, Marciniuk DD, Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial (NCT00120978). BMC Pulm Med 2006; 6:3.
   PubMedGoogle Scholar
• Decramer M, Rennard S, Troosters T COPD as a lung disease with systemic consequences–clinical impact, mechanisms, and potential for early intervention. COPD 2008; 5:235–256.
   PubMedGoogle Scholar
• Mannino DM, Doherty DE, Buist AS. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006; 100:115–122.
   PubMed Web of Science ®Google Scholar
• Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax 2008; 63:599–605.
   PubMed Web of Science ®Google Scholar
• Redman CM, Xia H. Fibrinogen biosynthesis. Assembly, intracellular degradation, and association with lipid synthesis and secretion. Ann NY Acad Sci 2001; 936:480–495.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TA, MacCallum PK, Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84:210–215.
   PubMed Web of Science ®Google Scholar
• Engstrom G, Lind P, Hedblad B, Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation 2002; 106:2555–2560.
   PubMed Web of Science ®Google Scholar
• Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1008–1011.
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH. Serum C-reactive protein and fibrinogen concentrations and self- reported angina pectoris and myocardial infarction: findings from National Health and Nutrition Examination Survey III. J Clin Epidemiol 2000; 53:95–102.
   PubMed Web of Science ®Google Scholar
• Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003; 114:758–762.
   PubMed Web of Science ®Google Scholar
• Gunter EW, Lewis B, Koncikowski S. Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, 1996.
   Google Scholar
• Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179–187.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Roisin R, Rabe KF, Anzueto A, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2008 Update). www.goldcopd.org. 2009. 4–26–2011.
   Google Scholar
• Lowe GD, Rumley A, Mackie IJ. Plasma fibrinogen. Ann Clin Biochem 2004; 41:430–440.
   PubMed Web of Science ®Google Scholar
• De Maat MP, Verschuur M. Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol 2005; 12:377–
383.
   PubMed Web of Science ®Google Scholar
• Engstrom G, Segelstorm N, Ekberg-Aronsson M, Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study. Thorax 2009; 64:211–215.
   PubMed Web of Science ®Google Scholar
• Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107:1514–1519.
   PubMed Web of Science ®Google Scholar
• Gunen H, Gulbas G, In E, Yetkin O, Hacievliyagil SS. Venous thromboemboli and exacerbations of COPD. Eur Respir J 2010; 35:1243–1248.
   PubMed Web of Science ®Google Scholar
• Hyatt RE, Cowl CT, Bjoraker JA, Scanlon PD. Conditions associated with an abnormal nonspecific pattern of pulmonary function tests. Chest 2009; 135:419–424.
   PubMed Web of Science ®Google Scholar
• Lomas DA, Miller BE, Willitis L, Keene O, Barnacle H, Barnes NC, Inhibition of p38 MAP kinase reduces plasma fibrinogen in COPD. J Clin Pharmacol. In press.
   PubMedGoogle Scholar